schliessen

Filtern

 

Bibliotheken

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments . Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies,... Full description

Journal Title: Nature medicine 2020-11, Vol.26 (11), p.1708-1713
Main Author: Liu, Sean T H
Other Authors: Lin, Hung-Mo , Baine, Ian , Wajnberg, Ania , Gumprecht, Jeffrey P , Rahman, Farah , Rodriguez, Denise , Tandon, Pranai , Bassily-Marcus, Adel , Bander, Jeffrey , Sanky, Charles , Dupper, Amy , Zheng, Allen , Nguyen, Freddy T , Amanat, Fatima , Stadlbauer, Daniel , Altman, Deena R , Chen, Benjamin K , Krammer, Florian , Mendu, Damodara Rao , Firpo-Betancourt, Adolfo , Levin, Matthew A , Bagiella, Emilia , Casadevall, Arturo , Cordon-Cardo, Carlos , Jhang, Jeffrey S , Arinsburg, Suzanne A , Reich, David L , Aberg, Judith A , Bouvier, Nicole M
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: United States: Nature Publishing Group
ID: ISSN: 1078-8956
Link: https://www.ncbi.nlm.nih.gov/pubmed/32934372
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_2443521242
title: Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study
format: Article
creator:
  • Liu, Sean T H
  • Lin, Hung-Mo
  • Baine, Ian
  • Wajnberg, Ania
  • Gumprecht, Jeffrey P
  • Rahman, Farah
  • Rodriguez, Denise
  • Tandon, Pranai
  • Bassily-Marcus, Adel
  • Bander, Jeffrey
  • Sanky, Charles
  • Dupper, Amy
  • Zheng, Allen
  • Nguyen, Freddy T
  • Amanat, Fatima
  • Stadlbauer, Daniel
  • Altman, Deena R
  • Chen, Benjamin K
  • Krammer, Florian
  • Mendu, Damodara Rao
  • Firpo-Betancourt, Adolfo
  • Levin, Matthew A
  • Bagiella, Emilia
  • Casadevall, Arturo
  • Cordon-Cardo, Carlos
  • Jhang, Jeffrey S
  • Arinsburg, Suzanne A
  • Reich, David L
  • Aberg, Judith A
  • Bouvier, Nicole M
subjects:
  • Adult
  • Aged
  • Antibodies
  • Antibodies, Viral - blood
  • Case-Control Studies
  • Chi-square test
  • Clinical trials
  • Confidence intervals
  • Coronaviruses
  • COVID-19
  • COVID-19 - epidemiology
  • COVID-19 - pathology
  • COVID-19 - therapy
  • Disease control
  • Female
  • Health services
  • Humans
  • Immunization, Passive
  • Infectious diseases
  • Male
  • Medical treatment
  • Middle Aged
  • Oxygen requirement
  • Pandemics
  • Patients
  • Plasma
  • Propensity Score
  • Public health
  • Respiratory diseases
  • Retrospective Studies
  • SARS-CoV-2 - immunology
  • Severe acute respiratory syndrome
  • Severe acute respiratory syndrome coronavirus 2
  • Severity of Illness Index
  • Statistical tests
  • Survival
  • Transfusion
  • Treatment Outcome
  • Vaccines
  • Viral diseases
  • Viruses
ispartof: Nature medicine, 2020-11, Vol.26 (11), p.1708-1713
description: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments . Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, including those that specifically recognize SARS-CoV-2. These antibodies, when transfused into patients infected with SARS-CoV-2, are thought to exert an antiviral effect, suppressing virus replication before patients have mounted their own humoral immune responses . Virus-specific antibodies from recovered persons are often the first available therapy for an emerging infectious disease, a stopgap treatment while new antivirals and vaccines are being developed . This retrospective, propensity score-matched case-control study assessed the effectiveness of convalescent plasma therapy in 39 patients with severe or life-threatening COVID-19 at The Mount Sinai Hospital in New York City. Oxygen requirements on day 14 after transfusion worsened in 17.9% of plasma recipients versus 28.2% of propensity score-matched controls who were hospitalized with COVID-19 (adjusted odds ratio (OR), 0.86; 95% confidence interval (CI), 0.75-0.98; chi-square test P value = 0.025). Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13-0.89; chi-square test P = 0.027). Convalescent plasma is potentially effective against COVID-19, but adequately powered, randomized controlled trials are needed.
language: eng
source:
identifier: ISSN: 1078-8956
fulltext: no_fulltext
issn:
  • 1078-8956
  • 1546-170X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.8895378
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_2443521242
sourceformatXML
sourcesystemPC
galeidA650810393
sourcerecordidA650810393
originalsourceidFETCH-LOGICAL-c462t-5bf88a9298237d9032af8d7a69455ba5be4e531d1a6111a6e7133290f3f804ba0
addsrcrecordideNp9ku1r1TAUxosobk7_AL9IQRD3ITOvbeK3cdV5YXDBlyF-CWl7stvRNjVJh_e_N-Xqto4hgSQcfufhnIcny14SfEIwk-8CJ0IRhClGBEuJ1KPskAheIFLiH4_TH5cSSSWKg-xZCFcYY4aFepodMKoYZyU9zH6u3HBtOgg1DDEfOxN6k0cPJvZzwdk8wDV4yFebi_UHRNT73OSjdyMMoY27PNTOA-pNrLfQ5LUbonddHuLU7J5nT6zpArz4-x5l3z99_Lb6jM43Z-vV6TmqeUEjEpWV0iiqJGVlozCjxsqmNIXiQlRGVMBBMNIQUxCSLigJS_Njy6zEvDL4KHu7101j_ZogRN23aZ2uMwO4KWjKOROUUE4T-voeeuUmP6TpElWyGSLilrpMxuh2sC56U8-i-rQQWCbvFUvUyQNUOg30bTICbJvqi4ZXDzTou8DxApjdhN_x0kwh6PXXL0ux_7GbiyX75g67BdPFbXDdFFs3hCVI9mDtXQgerB592xu_0wTrOXF6nzidEqfnxGl1u9U4VT00Nx3_Iob_AFj2yW8
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid2473212415
display
typearticle
titleConvalescent plasma treatment of severe COVID-19: a propensity score-matched control study
creatorLiu, Sean T H ; Lin, Hung-Mo ; Baine, Ian ; Wajnberg, Ania ; Gumprecht, Jeffrey P ; Rahman, Farah ; Rodriguez, Denise ; Tandon, Pranai ; Bassily-Marcus, Adel ; Bander, Jeffrey ; Sanky, Charles ; Dupper, Amy ; Zheng, Allen ; Nguyen, Freddy T ; Amanat, Fatima ; Stadlbauer, Daniel ; Altman, Deena R ; Chen, Benjamin K ; Krammer, Florian ; Mendu, Damodara Rao ; Firpo-Betancourt, Adolfo ; Levin, Matthew A ; Bagiella, Emilia ; Casadevall, Arturo ; Cordon-Cardo, Carlos ; Jhang, Jeffrey S ; Arinsburg, Suzanne A ; Reich, David L ; Aberg, Judith A ; Bouvier, Nicole M
creatorcontribLiu, Sean T H ; Lin, Hung-Mo ; Baine, Ian ; Wajnberg, Ania ; Gumprecht, Jeffrey P ; Rahman, Farah ; Rodriguez, Denise ; Tandon, Pranai ; Bassily-Marcus, Adel ; Bander, Jeffrey ; Sanky, Charles ; Dupper, Amy ; Zheng, Allen ; Nguyen, Freddy T ; Amanat, Fatima ; Stadlbauer, Daniel ; Altman, Deena R ; Chen, Benjamin K ; Krammer, Florian ; Mendu, Damodara Rao ; Firpo-Betancourt, Adolfo ; Levin, Matthew A ; Bagiella, Emilia ; Casadevall, Arturo ; Cordon-Cardo, Carlos ; Jhang, Jeffrey S ; Arinsburg, Suzanne A ; Reich, David L ; Aberg, Judith A ; Bouvier, Nicole M
descriptionCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments . Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, including those that specifically recognize SARS-CoV-2. These antibodies, when transfused into patients infected with SARS-CoV-2, are thought to exert an antiviral effect, suppressing virus replication before patients have mounted their own humoral immune responses . Virus-specific antibodies from recovered persons are often the first available therapy for an emerging infectious disease, a stopgap treatment while new antivirals and vaccines are being developed . This retrospective, propensity score-matched case-control study assessed the effectiveness of convalescent plasma therapy in 39 patients with severe or life-threatening COVID-19 at The Mount Sinai Hospital in New York City. Oxygen requirements on day 14 after transfusion worsened in 17.9% of plasma recipients versus 28.2% of propensity score-matched controls who were hospitalized with COVID-19 (adjusted odds ratio (OR), 0.86; 95% confidence interval (CI), 0.75-0.98; chi-square test P value = 0.025). Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13-0.89; chi-square test P = 0.027). Convalescent plasma is potentially effective against COVID-19, but adequately powered, randomized controlled trials are needed.
identifier
0ISSN: 1078-8956
1EISSN: 1546-170X
2DOI: 10.1038/s41591-020-1088-9
3PMID: 32934372
languageeng
publisherUnited States: Nature Publishing Group
subjectAdult ; Aged ; Antibodies ; Antibodies, Viral - blood ; Case-Control Studies ; Chi-square test ; Clinical trials ; Confidence intervals ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - pathology ; COVID-19 - therapy ; Disease control ; Female ; Health services ; Humans ; Immunization, Passive ; Infectious diseases ; Male ; Medical treatment ; Middle Aged ; Oxygen requirement ; Pandemics ; Patients ; Plasma ; Propensity Score ; Public health ; Respiratory diseases ; Retrospective Studies ; SARS-CoV-2 - immunology ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Severity of Illness Index ; Statistical tests ; Survival ; Transfusion ; Treatment Outcome ; Vaccines ; Viral diseases ; Viruses
ispartofNature medicine, 2020-11, Vol.26 (11), p.1708-1713
rightsThe Author(s), under exclusive licence to Springer Nature America, Inc. 2020.
lds50peer_reviewed
oafree_for_read
citesFETCH-LOGICAL-c462t-5bf88a9298237d9032af8d7a69455ba5be4e531d1a6111a6e7133290f3f804ba0
orcidid0000-0001-8162-0284 ; 0000-0002-4530-2841 ; 0000-0003-4121-776X ; 0000-0001-6792-7650 ; 0000-0003-1948-3834 ; 0000-0002-6013-2684 ; 0000-0002-3842-6838 ; 0000-0003-0106-8114 ; 0000-0003-1103-839X
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32934372$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Liu, Sean T H
1Lin, Hung-Mo
2Baine, Ian
3Wajnberg, Ania
4Gumprecht, Jeffrey P
5Rahman, Farah
6Rodriguez, Denise
7Tandon, Pranai
8Bassily-Marcus, Adel
9Bander, Jeffrey
10Sanky, Charles
11Dupper, Amy
12Zheng, Allen
13Nguyen, Freddy T
14Amanat, Fatima
15Stadlbauer, Daniel
16Altman, Deena R
17Chen, Benjamin K
18Krammer, Florian
19Mendu, Damodara Rao
20Firpo-Betancourt, Adolfo
21Levin, Matthew A
22Bagiella, Emilia
23Casadevall, Arturo
24Cordon-Cardo, Carlos
25Jhang, Jeffrey S
26Arinsburg, Suzanne A
27Reich, David L
28Aberg, Judith A
29Bouvier, Nicole M
title
0Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study
1Nature medicine
addtitleNat Med
descriptionCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments . Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, including those that specifically recognize SARS-CoV-2. These antibodies, when transfused into patients infected with SARS-CoV-2, are thought to exert an antiviral effect, suppressing virus replication before patients have mounted their own humoral immune responses . Virus-specific antibodies from recovered persons are often the first available therapy for an emerging infectious disease, a stopgap treatment while new antivirals and vaccines are being developed . This retrospective, propensity score-matched case-control study assessed the effectiveness of convalescent plasma therapy in 39 patients with severe or life-threatening COVID-19 at The Mount Sinai Hospital in New York City. Oxygen requirements on day 14 after transfusion worsened in 17.9% of plasma recipients versus 28.2% of propensity score-matched controls who were hospitalized with COVID-19 (adjusted odds ratio (OR), 0.86; 95% confidence interval (CI), 0.75-0.98; chi-square test P value = 0.025). Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13-0.89; chi-square test P = 0.027). Convalescent plasma is potentially effective against COVID-19, but adequately powered, randomized controlled trials are needed.
subject
0Adult
1Aged
2Antibodies
3Antibodies, Viral - blood
4Case-Control Studies
5Chi-square test
6Clinical trials
7Confidence intervals
8Coronaviruses
9COVID-19
10COVID-19 - epidemiology
11COVID-19 - pathology
12COVID-19 - therapy
13Disease control
14Female
15Health services
16Humans
17Immunization, Passive
18Infectious diseases
19Male
20Medical treatment
21Middle Aged
22Oxygen requirement
23Pandemics
24Patients
25Plasma
26Propensity Score
27Public health
28Respiratory diseases
29Retrospective Studies
30SARS-CoV-2 - immunology
31Severe acute respiratory syndrome
32Severe acute respiratory syndrome coronavirus 2
33Severity of Illness Index
34Statistical tests
35Survival
36Transfusion
37Treatment Outcome
38Vaccines
39Viral diseases
40Viruses
issn
01078-8956
11546-170X
fulltextfalse
rsrctypearticle
creationdate2020
recordtypearticle
recordideNp9ku1r1TAUxosobk7_AL9IQRD3ITOvbeK3cdV5YXDBlyF-CWl7stvRNjVJh_e_N-Xqto4hgSQcfufhnIcny14SfEIwk-8CJ0IRhClGBEuJ1KPskAheIFLiH4_TH5cSSSWKg-xZCFcYY4aFepodMKoYZyU9zH6u3HBtOgg1DDEfOxN6k0cPJvZzwdk8wDV4yFebi_UHRNT73OSjdyMMoY27PNTOA-pNrLfQ5LUbonddHuLU7J5nT6zpArz4-x5l3z99_Lb6jM43Z-vV6TmqeUEjEpWV0iiqJGVlozCjxsqmNIXiQlRGVMBBMNIQUxCSLigJS_Njy6zEvDL4KHu7101j_ZogRN23aZ2uMwO4KWjKOROUUE4T-voeeuUmP6TpElWyGSLilrpMxuh2sC56U8-i-rQQWCbvFUvUyQNUOg30bTICbJvqi4ZXDzTou8DxApjdhN_x0kwh6PXXL0ux_7GbiyX75g67BdPFbXDdFFs3hCVI9mDtXQgerB592xu_0wTrOXF6nzidEqfnxGl1u9U4VT00Nx3_Iob_AFj2yW8
startdate202011
enddate202011
creator
0Liu, Sean T H
1Lin, Hung-Mo
2Baine, Ian
3Wajnberg, Ania
4Gumprecht, Jeffrey P
5Rahman, Farah
6Rodriguez, Denise
7Tandon, Pranai
8Bassily-Marcus, Adel
9Bander, Jeffrey
10Sanky, Charles
11Dupper, Amy
12Zheng, Allen
13Nguyen, Freddy T
14Amanat, Fatima
15Stadlbauer, Daniel
16Altman, Deena R
17Chen, Benjamin K
18Krammer, Florian
19Mendu, Damodara Rao
20Firpo-Betancourt, Adolfo
21Levin, Matthew A
22Bagiella, Emilia
23Casadevall, Arturo
24Cordon-Cardo, Carlos
25Jhang, Jeffrey S
26Arinsburg, Suzanne A
27Reich, David L
28Aberg, Judith A
29Bouvier, Nicole M
generalNature Publishing Group
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BKMMT
9BSHEE
103V.
117QG
127QL
137QP
147QR
157T5
167TK
177TM
187TO
197U7
207U9
217X7
227XB
2388A
2488E
2588I
268AO
278FD
288FE
298FH
308FI
318FJ
328FK
338G5
34ABUWG
35AZQEC
36BBNVY
37BENPR
38BHPHI
39C1K
40DWQXO
41FR3
42FYUFA
43GHDGH
44GNUQQ
45GUQSH
46H94
47HCIFZ
48K9.
49LK8
50M0S
51M1P
52M2O
53M2P
54M7N
55M7P
56MBDVC
57P64
58PADUT
59PQEST
60PQQKQ
61PQUKI
62PRINS
63Q9U
64RC3
657X8
orcidid
0https://orcid.org/0000-0001-8162-0284
1https://orcid.org/0000-0002-4530-2841
2https://orcid.org/0000-0003-4121-776X
3https://orcid.org/0000-0001-6792-7650
4https://orcid.org/0000-0003-1948-3834
5https://orcid.org/0000-0002-6013-2684
6https://orcid.org/0000-0002-3842-6838
7https://orcid.org/0000-0003-0106-8114
8https://orcid.org/0000-0003-1103-839X
sort
creationdate202011
titleConvalescent plasma treatment of severe COVID-19: a propensity score-matched control study
authorLiu, Sean T H ; Lin, Hung-Mo ; Baine, Ian ; Wajnberg, Ania ; Gumprecht, Jeffrey P ; Rahman, Farah ; Rodriguez, Denise ; Tandon, Pranai ; Bassily-Marcus, Adel ; Bander, Jeffrey ; Sanky, Charles ; Dupper, Amy ; Zheng, Allen ; Nguyen, Freddy T ; Amanat, Fatima ; Stadlbauer, Daniel ; Altman, Deena R ; Chen, Benjamin K ; Krammer, Florian ; Mendu, Damodara Rao ; Firpo-Betancourt, Adolfo ; Levin, Matthew A ; Bagiella, Emilia ; Casadevall, Arturo ; Cordon-Cardo, Carlos ; Jhang, Jeffrey S ; Arinsburg, Suzanne A ; Reich, David L ; Aberg, Judith A ; Bouvier, Nicole M
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c462t-5bf88a9298237d9032af8d7a69455ba5be4e531d1a6111a6e7133290f3f804ba0
rsrctypearticles
prefilterarticles
languageeng
creationdate2020
topic
0Adult
1Aged
2Antibodies
3Antibodies, Viral - blood
4Case-Control Studies
5Chi-square test
6Clinical trials
7Confidence intervals
8Coronaviruses
9COVID-19
10COVID-19 - epidemiology
11COVID-19 - pathology
12COVID-19 - therapy
13Disease control
14Female
15Health services
16Humans
17Immunization, Passive
18Infectious diseases
19Male
20Medical treatment
21Middle Aged
22Oxygen requirement
23Pandemics
24Patients
25Plasma
26Propensity Score
27Public health
28Respiratory diseases
29Retrospective Studies
30SARS-CoV-2 - immunology
31Severe acute respiratory syndrome
32Severe acute respiratory syndrome coronavirus 2
33Severity of Illness Index
34Statistical tests
35Survival
36Transfusion
37Treatment Outcome
38Vaccines
39Viral diseases
40Viruses
toplevelpeer_reviewed
creatorcontrib
0Liu, Sean T H
1Lin, Hung-Mo
2Baine, Ian
3Wajnberg, Ania
4Gumprecht, Jeffrey P
5Rahman, Farah
6Rodriguez, Denise
7Tandon, Pranai
8Bassily-Marcus, Adel
9Bander, Jeffrey
10Sanky, Charles
11Dupper, Amy
12Zheng, Allen
13Nguyen, Freddy T
14Amanat, Fatima
15Stadlbauer, Daniel
16Altman, Deena R
17Chen, Benjamin K
18Krammer, Florian
19Mendu, Damodara Rao
20Firpo-Betancourt, Adolfo
21Levin, Matthew A
22Bagiella, Emilia
23Casadevall, Arturo
24Cordon-Cardo, Carlos
25Jhang, Jeffrey S
26Arinsburg, Suzanne A
27Reich, David L
28Aberg, Judith A
29Bouvier, Nicole M
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Gale General OneFile (A&I only)
8Academic OneFile (A&I only)
9ProQuest Central (Corporate)
10Animal Behavior Abstracts
11Bacteriology Abstracts (Microbiology B)
12Calcium & Calcified Tissue Abstracts
13Chemoreception Abstracts
14Immunology Abstracts
15Neurosciences Abstracts
16Nucleic Acids Abstracts
17Oncogenes and Growth Factors Abstracts
18Toxicology Abstracts
19Virology and AIDS Abstracts
20Health & Medical Collection
21ProQuest Central (purchase pre-March 2016)
22Biology Database (Alumni Edition)
23Medical Database (Alumni Edition)
24Science Database (Alumni Edition)
25ProQuest Pharma Collection
26Technology Research Database
27ProQuest SciTech Collection
28ProQuest Natural Science Collection
29Hospital Premium Collection
30Hospital Premium Collection (Alumni Edition)
31ProQuest Central (Alumni) (purchase pre-March 2016)
32Research Library (Alumni Edition)
33ProQuest Central (Alumni Edition)
34ProQuest Central Essentials
35Biological Science Collection
36ProQuest Central
37Natural Science Collection
38Environmental Sciences and Pollution Management
39ProQuest Central Korea
40Engineering Research Database
41Health Research Premium Collection
42Health Research Premium Collection (Alumni)
43ProQuest Central Student
44Research Library Prep
45AIDS and Cancer Research Abstracts
46SciTech Premium Collection
47ProQuest Health & Medical Complete (Alumni)
48ProQuest Biological Science Collection
49Health & Medical Collection (Alumni Edition)
50Medical Database
51Research Library
52Science Database
53Algology Mycology and Protozoology Abstracts (Microbiology C)
54Biological Science Database
55Research Library (Corporate)
56Biotechnology and BioEngineering Abstracts
57Research Library China
58ProQuest One Academic Eastern Edition
59ProQuest One Academic
60ProQuest One Academic UKI Edition
61ProQuest Central China
62ProQuest Central Basic
63Genetics Abstracts
64MEDLINE - Academic
jtitleNature medicine
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Liu, Sean T H
1Lin, Hung-Mo
2Baine, Ian
3Wajnberg, Ania
4Gumprecht, Jeffrey P
5Rahman, Farah
6Rodriguez, Denise
7Tandon, Pranai
8Bassily-Marcus, Adel
9Bander, Jeffrey
10Sanky, Charles
11Dupper, Amy
12Zheng, Allen
13Nguyen, Freddy T
14Amanat, Fatima
15Stadlbauer, Daniel
16Altman, Deena R
17Chen, Benjamin K
18Krammer, Florian
19Mendu, Damodara Rao
20Firpo-Betancourt, Adolfo
21Levin, Matthew A
22Bagiella, Emilia
23Casadevall, Arturo
24Cordon-Cardo, Carlos
25Jhang, Jeffrey S
26Arinsburg, Suzanne A
27Reich, David L
28Aberg, Judith A
29Bouvier, Nicole M
formatjournal
genrearticle
ristypeJOUR
atitleConvalescent plasma treatment of severe COVID-19: a propensity score-matched control study
jtitleNature medicine
addtitleNat Med
date2020-11
risdate2020
volume26
issue11
spage1708
epage1713
pages1708-1713
issn1078-8956
eissn1546-170X
abstractCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments . Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, including those that specifically recognize SARS-CoV-2. These antibodies, when transfused into patients infected with SARS-CoV-2, are thought to exert an antiviral effect, suppressing virus replication before patients have mounted their own humoral immune responses . Virus-specific antibodies from recovered persons are often the first available therapy for an emerging infectious disease, a stopgap treatment while new antivirals and vaccines are being developed . This retrospective, propensity score-matched case-control study assessed the effectiveness of convalescent plasma therapy in 39 patients with severe or life-threatening COVID-19 at The Mount Sinai Hospital in New York City. Oxygen requirements on day 14 after transfusion worsened in 17.9% of plasma recipients versus 28.2% of propensity score-matched controls who were hospitalized with COVID-19 (adjusted odds ratio (OR), 0.86; 95% confidence interval (CI), 0.75-0.98; chi-square test P value = 0.025). Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13-0.89; chi-square test P = 0.027). Convalescent plasma is potentially effective against COVID-19, but adequately powered, randomized controlled trials are needed.
copUnited States
pubNature Publishing Group
pmid32934372
doi10.1038/s41591-020-1088-9
tpages6
orcidid
0https://orcid.org/0000-0001-8162-0284
1https://orcid.org/0000-0002-4530-2841
2https://orcid.org/0000-0003-4121-776X
3https://orcid.org/0000-0001-6792-7650
4https://orcid.org/0000-0003-1948-3834
5https://orcid.org/0000-0002-6013-2684
6https://orcid.org/0000-0002-3842-6838
7https://orcid.org/0000-0003-0106-8114
8https://orcid.org/0000-0003-1103-839X
oafree_for_read